Market closed
Black Diamond Therapeutics/BDTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Black Diamond Therapeutics
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
Ticker
BDTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
54
BDTX Metrics
BasicAdvanced
$172M
Market cap
-
P/E ratio
-$1.54
EPS
2.49
Beta
-
Dividend rate
Price and volume
Market cap
$172M
Beta
2.49
52-week high
$7.66
52-week low
$1.62
Average daily volume
1.9M
Financial strength
Current ratio
6.874
Quick ratio
6.669
Long term debt to equity
18.488
Total debt to equity
21.421
Management effectiveness
Return on assets (TTM)
-40.41%
Return on equity (TTM)
-83.38%
Valuation
Price to book
1.54
Price to tangible book (TTM)
1.54
Price to free cash flow (TTM)
-2.335
Growth
Earnings per share change (TTM)
-32.38%
3-year earnings per share growth (CAGR)
-19.29%
What the Analysts think about BDTX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Black Diamond Therapeutics stock.
BDTX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
BDTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
BDTX News
AllArticlesVideos
Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data
Seeking Alpha·3 weeks ago
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
GlobeNewsWire·3 weeks ago
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Black Diamond Therapeutics stock?
Black Diamond Therapeutics (BDTX) has a market cap of $172M as of October 26, 2024.
What is the P/E ratio for Black Diamond Therapeutics stock?
The price to earnings (P/E) ratio for Black Diamond Therapeutics (BDTX) stock is 0 as of October 26, 2024.
Does Black Diamond Therapeutics stock pay dividends?
No, Black Diamond Therapeutics (BDTX) stock does not pay dividends to its shareholders as of October 26, 2024.
When is the next Black Diamond Therapeutics dividend payment date?
Black Diamond Therapeutics (BDTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Black Diamond Therapeutics?
Black Diamond Therapeutics (BDTX) has a beta rating of 2.49. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.